Usefulness of CHA2DS2-VASc Score to Predict Stroke Risk Independent of Atrial Fibrillation

Anne Gulbech Ording, E. Puhó, P. Prandoni, Michelle Zippora Leisner, Dóra Körmendiné Farkas, Flemming Hald Steffensen, Morten Olsen, Henrik Toft Sørensen, Morten Schmidt

Research output: Contribution to journalArticle

Abstract

The CHA2DS2-VASc score is used to predict stroke risk among patients with atrial fibrillation (AF). We examined whether a CHA2DS2-VASc score predicts stroke risk among individuals without hospital-diagnosed AF and quantified the magnitude of the association in comparison to AF patients. We used data from population-based medical registries (1995 to 2005) covering all Danish hospitals to identify patients diagnosed with AF (n = 122,980). We matched ≤5 non-AF individuals (n = 612,723) to each AF patient on the individual risk factors included in the CHA2DS2-VASc score. We calculated 10-year absolute risk of ischemic and all-cause stroke in AF and non-AF individuals and compared the stroke risk between cohorts within strata of CHA2DS2-VASc scores using Cox regression. The 10-year risk of ischemic/all-cause stroke was 4.4%/8.8% among non-AF individuals and 6.2%/12% in AF patients, corresponding to a risk difference of 1.8% for ischemic stroke and 3.3% for all-cause stroke. In both cohorts, the stroke risk correlated with increasing CHA2DS2-VASc scores. However, in individuals with CHA2DS2-VASc scores ≥5 who were <75 years or male, the absolute risk of ischemic stroke in individuals without AF exceeded the risk in AF patients. In the same subgroups, the hazard ratio approached unity. Similar results were observed for all-cause stroke. The CHA2DS2-VASc score was associated with 10-year stroke risk also among individuals without hospital-diagnosed AF. In conclusion, primary prophylactic anticoagulation therapy may be relevant in male and younger non-AF individuals with CHA2DS2-VASc scores ≥5. These findings should be confirmed in clinical trials.

Original languageEnglish
JournalAmerican Journal of Cardiology
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Atrial Fibrillation
Stroke
Registries
Clinical Trials

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Usefulness of CHA2DS2-VASc Score to Predict Stroke Risk Independent of Atrial Fibrillation. / Ording, Anne Gulbech; Puhó, E.; Prandoni, P.; Leisner, Michelle Zippora; Farkas, Dóra Körmendiné; Steffensen, Flemming Hald; Olsen, Morten; Sørensen, Henrik Toft; Schmidt, Morten.

In: American Journal of Cardiology, 01.01.2019.

Research output: Contribution to journalArticle

Ording, Anne Gulbech ; Puhó, E. ; Prandoni, P. ; Leisner, Michelle Zippora ; Farkas, Dóra Körmendiné ; Steffensen, Flemming Hald ; Olsen, Morten ; Sørensen, Henrik Toft ; Schmidt, Morten. / Usefulness of CHA2DS2-VASc Score to Predict Stroke Risk Independent of Atrial Fibrillation. In: American Journal of Cardiology. 2019.
@article{0dbfddd4d17843a7966c171724fbf46d,
title = "Usefulness of CHA2DS2-VASc Score to Predict Stroke Risk Independent of Atrial Fibrillation",
abstract = "The CHA2DS2-VASc score is used to predict stroke risk among patients with atrial fibrillation (AF). We examined whether a CHA2DS2-VASc score predicts stroke risk among individuals without hospital-diagnosed AF and quantified the magnitude of the association in comparison to AF patients. We used data from population-based medical registries (1995 to 2005) covering all Danish hospitals to identify patients diagnosed with AF (n = 122,980). We matched ≤5 non-AF individuals (n = 612,723) to each AF patient on the individual risk factors included in the CHA2DS2-VASc score. We calculated 10-year absolute risk of ischemic and all-cause stroke in AF and non-AF individuals and compared the stroke risk between cohorts within strata of CHA2DS2-VASc scores using Cox regression. The 10-year risk of ischemic/all-cause stroke was 4.4{\%}/8.8{\%} among non-AF individuals and 6.2{\%}/12{\%} in AF patients, corresponding to a risk difference of 1.8{\%} for ischemic stroke and 3.3{\%} for all-cause stroke. In both cohorts, the stroke risk correlated with increasing CHA2DS2-VASc scores. However, in individuals with CHA2DS2-VASc scores ≥5 who were <75 years or male, the absolute risk of ischemic stroke in individuals without AF exceeded the risk in AF patients. In the same subgroups, the hazard ratio approached unity. Similar results were observed for all-cause stroke. The CHA2DS2-VASc score was associated with 10-year stroke risk also among individuals without hospital-diagnosed AF. In conclusion, primary prophylactic anticoagulation therapy may be relevant in male and younger non-AF individuals with CHA2DS2-VASc scores ≥5. These findings should be confirmed in clinical trials.",
author = "Ording, {Anne Gulbech} and E. Puh{\'o} and P. Prandoni and Leisner, {Michelle Zippora} and Farkas, {D{\'o}ra K{\"o}rmendin{\'e}} and Steffensen, {Flemming Hald} and Morten Olsen and S{\o}rensen, {Henrik Toft} and Morten Schmidt",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.amjcard.2019.06.028",
language = "English",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Usefulness of CHA2DS2-VASc Score to Predict Stroke Risk Independent of Atrial Fibrillation

AU - Ording, Anne Gulbech

AU - Puhó, E.

AU - Prandoni, P.

AU - Leisner, Michelle Zippora

AU - Farkas, Dóra Körmendiné

AU - Steffensen, Flemming Hald

AU - Olsen, Morten

AU - Sørensen, Henrik Toft

AU - Schmidt, Morten

PY - 2019/1/1

Y1 - 2019/1/1

N2 - The CHA2DS2-VASc score is used to predict stroke risk among patients with atrial fibrillation (AF). We examined whether a CHA2DS2-VASc score predicts stroke risk among individuals without hospital-diagnosed AF and quantified the magnitude of the association in comparison to AF patients. We used data from population-based medical registries (1995 to 2005) covering all Danish hospitals to identify patients diagnosed with AF (n = 122,980). We matched ≤5 non-AF individuals (n = 612,723) to each AF patient on the individual risk factors included in the CHA2DS2-VASc score. We calculated 10-year absolute risk of ischemic and all-cause stroke in AF and non-AF individuals and compared the stroke risk between cohorts within strata of CHA2DS2-VASc scores using Cox regression. The 10-year risk of ischemic/all-cause stroke was 4.4%/8.8% among non-AF individuals and 6.2%/12% in AF patients, corresponding to a risk difference of 1.8% for ischemic stroke and 3.3% for all-cause stroke. In both cohorts, the stroke risk correlated with increasing CHA2DS2-VASc scores. However, in individuals with CHA2DS2-VASc scores ≥5 who were <75 years or male, the absolute risk of ischemic stroke in individuals without AF exceeded the risk in AF patients. In the same subgroups, the hazard ratio approached unity. Similar results were observed for all-cause stroke. The CHA2DS2-VASc score was associated with 10-year stroke risk also among individuals without hospital-diagnosed AF. In conclusion, primary prophylactic anticoagulation therapy may be relevant in male and younger non-AF individuals with CHA2DS2-VASc scores ≥5. These findings should be confirmed in clinical trials.

AB - The CHA2DS2-VASc score is used to predict stroke risk among patients with atrial fibrillation (AF). We examined whether a CHA2DS2-VASc score predicts stroke risk among individuals without hospital-diagnosed AF and quantified the magnitude of the association in comparison to AF patients. We used data from population-based medical registries (1995 to 2005) covering all Danish hospitals to identify patients diagnosed with AF (n = 122,980). We matched ≤5 non-AF individuals (n = 612,723) to each AF patient on the individual risk factors included in the CHA2DS2-VASc score. We calculated 10-year absolute risk of ischemic and all-cause stroke in AF and non-AF individuals and compared the stroke risk between cohorts within strata of CHA2DS2-VASc scores using Cox regression. The 10-year risk of ischemic/all-cause stroke was 4.4%/8.8% among non-AF individuals and 6.2%/12% in AF patients, corresponding to a risk difference of 1.8% for ischemic stroke and 3.3% for all-cause stroke. In both cohorts, the stroke risk correlated with increasing CHA2DS2-VASc scores. However, in individuals with CHA2DS2-VASc scores ≥5 who were <75 years or male, the absolute risk of ischemic stroke in individuals without AF exceeded the risk in AF patients. In the same subgroups, the hazard ratio approached unity. Similar results were observed for all-cause stroke. The CHA2DS2-VASc score was associated with 10-year stroke risk also among individuals without hospital-diagnosed AF. In conclusion, primary prophylactic anticoagulation therapy may be relevant in male and younger non-AF individuals with CHA2DS2-VASc scores ≥5. These findings should be confirmed in clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=85069959093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069959093&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2019.06.028

DO - 10.1016/j.amjcard.2019.06.028

M3 - Article

AN - SCOPUS:85069959093

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

ER -